AGILE THERAPEUTICS INC

2024 Q3 Form 10-Q Financial Statement

#000155837024011904 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.848M
YoY Change 2.26%
Cash & Equivalents $2.848M
Short-Term Investments
Other Short-Term Assets $1.252M
YoY Change -32.9%
Inventory $5.793M
Prepaid Expenses
Receivables $4.550M
Other Receivables $0.00
Total Short-Term Assets $14.44M
YoY Change 23.98%
LONG-TERM ASSETS
Property, Plant & Equipment $27.00K
YoY Change -78.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $238.0K
YoY Change 0.0%
Total Long-Term Assets $520.0K
YoY Change -43.6%
TOTAL ASSETS
Total Short-Term Assets $14.44M
Total Long-Term Assets $520.0K
Total Assets $14.96M
YoY Change 19.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.54M
YoY Change 168.73%
Accrued Expenses $9.396M
YoY Change 39.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $26.23M
YoY Change 71.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $10.65M
YoY Change 13.47%
Total Long-Term Liabilities $10.65M
YoY Change 13.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.23M
Total Long-Term Liabilities $10.65M
Total Liabilities $36.88M
YoY Change 49.34%
SHAREHOLDERS EQUITY
Retained Earnings -$433.8M
YoY Change 3.8%
Common Stock $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$21.91M
YoY Change
Total Liabilities & Shareholders Equity $14.96M
YoY Change 19.03%

Cashflow Statement

Concept 2024 Q3 2024 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6904498
dei Entity Central Index Key
EntityCentralIndexKey
0001261249
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
AGILE THERAPEUTICS INC
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2963657
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46605134
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
932101
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36464
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
23-2936302
dei Entity Address Address Line1
EntityAddressAddressLine1
500 College Road East, Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
683-1880
dei Security12g Title
Security12gTitle
Common Stock, par value $0.0001 per share
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6904498
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2848000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2557000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4550000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3392000
CY2024Q2 us-gaap Inventory Net
InventoryNet
5793000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2738000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1252000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
843000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
14443000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9530000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
255000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
412000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
238000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
238000
CY2024Q2 us-gaap Assets
Assets
14963000
CY2023Q4 us-gaap Assets
Assets
10255000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1515000
CY2023Q4 agrx Note Payable Current
NotePayableCurrent
191000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
16543000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9574000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9396000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9131000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
289000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
366000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
26228000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20777000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
10647000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5696000
CY2024Q2 us-gaap Liabilities
Liabilities
36875000
CY2023Q4 us-gaap Liabilities
Liabilities
26573000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4850
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6904498
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2963657
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
411839000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
406846000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433756000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-423168000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-21912000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-16318000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14963000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10255000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5576000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5503000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11292000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9316000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
1496000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
2307000
us-gaap Cost Of Revenue
CostOfRevenue
3176000
us-gaap Cost Of Revenue
CostOfRevenue
4310000
CY2024Q2 us-gaap Gross Profit
GrossProfit
4080000
CY2023Q2 us-gaap Gross Profit
GrossProfit
3196000
us-gaap Gross Profit
GrossProfit
8116000
us-gaap Gross Profit
GrossProfit
5006000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
538000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
703000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1033000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1466000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3776000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4570000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7460000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9240000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2512000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3049000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5129000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6133000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
6826000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
8322000
us-gaap Operating Expenses
OperatingExpenses
13622000
us-gaap Operating Expenses
OperatingExpenses
16839000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2746000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5126000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5506000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11833000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
us-gaap Investment Income Interest
InvestmentIncomeInterest
52000
us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
CY2023Q2 us-gaap Interest Expense
InterestExpense
372000
us-gaap Interest Expense
InterestExpense
185000
us-gaap Interest Expense
InterestExpense
773000
CY2024Q2 us-gaap Derivative Excluded Component Gain Loss Recognized In Earnings
DerivativeExcludedComponentGainLossRecognizedInEarnings
-9154000
CY2023Q2 us-gaap Derivative Excluded Component Gain Loss Recognized In Earnings
DerivativeExcludedComponentGainLossRecognizedInEarnings
1674000
us-gaap Derivative Excluded Component Gain Loss Recognized In Earnings
DerivativeExcludedComponentGainLossRecognizedInEarnings
-4951000
us-gaap Derivative Excluded Component Gain Loss Recognized In Earnings
DerivativeExcludedComponentGainLossRecognizedInEarnings
3361000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9126000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1317000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5084000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2636000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11872000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3809000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10590000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9197000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3809000
us-gaap Net Income Loss
NetIncomeLoss
-10590000
us-gaap Net Income Loss
NetIncomeLoss
-9197000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.73
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.73
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.15
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.85
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6856229
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6856229
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1769803
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1769803
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5744066
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5744066
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1343293
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1343293
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-16318000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
333000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4377000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
1284000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-10324000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
284000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-21912000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5545000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
498000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5389000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9433000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
482000
CY2023Q2 agrx Adjustments To Additional Paid In Capital Reverse Stock Splits
AdjustmentsToAdditionalPaidInCapitalReverseStockSplits
-13000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3809000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-12121000
us-gaap Profit Loss
ProfitLoss
-10590000
us-gaap Profit Loss
ProfitLoss
-9197000
us-gaap Depreciation
Depreciation
48000
us-gaap Depreciation
Depreciation
51000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
157000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
137000
us-gaap Share Based Compensation
ShareBasedCompensation
618000
us-gaap Share Based Compensation
ShareBasedCompensation
979000
us-gaap Paid In Kind Interest
PaidInKindInterest
135000
us-gaap Paid In Kind Interest
PaidInKindInterest
586000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4951000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3361000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1158000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1084000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3055000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1204000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
408000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1873000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7236000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1260000
us-gaap Operating Lease Payments
OperatingLeasePayments
177000
us-gaap Operating Lease Payments
OperatingLeasePayments
154000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2243000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10114000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4376000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6509000
us-gaap Repayments Of Debt
RepaymentsOfDebt
1650000
us-gaap Repayments Of Debt
RepaymentsOfDebt
450000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
191000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
61000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2535000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7653000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
292000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2461000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2556000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5246000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2848000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2785000
us-gaap Interest Paid Net
InterestPaidNet
50000
us-gaap Interest Paid Net
InterestPaidNet
93000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433800000
CY2024Q2 agrx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
2800000
agrx Working Capital Deficit
WorkingCapitalDeficit
11800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, inventory reserves, the accounting for common stock warrants, stock-based compensation, and accounting for research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.</p>
agrx Inventory Reserves
InventoryReserves
1400000
CY2023 agrx Inventory Reserves
InventoryReserves
1400000
us-gaap Advertising Expense
AdvertisingExpense
0
CY2023Q2 us-gaap Advertising Expense
AdvertisingExpense
0
us-gaap Advertising Expense
AdvertisingExpense
0
CY2024Q2 us-gaap Advertising Expense
AdvertisingExpense
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Financial instruments, which potentially subject the Company to credit risk, consist principally of cash, cash equivalents, and accounts receivable. The Company invests its cash and cash equivalents in interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity, and have a high credit quality. The Company has not recognized any losses from credit risks on such accounts. The Company has </span>no financial instruments with off balance sheet risk of accounting loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three months ended June 30, 2024, the Company had sales to six customers that individually accounted for more than 10% of its total revenue. These customers had sales of $1.1 million, $1.0 million, $1.0 million, $0.8 million, $0.7 million, and $0.5 million, respectively, which represented 92% of total revenues in the three months ended June 30, 2024. In the six months ended June 30, 2024, the Company had sales to six customers that individually accounted for more than 10% of its total revenue. These customers had sales of $2.1 million, $2.0 million, $1.8 million, $1.7 million, $1.6 million, and $1.3 million, respectively, which represented 93% of total revenues in the six months ended June 30, 2024. Accounts receivable related to these six customers totaled 97% of the Company’s total accounts receivable as of June 30, 2024. In the three months ended June 30, 2023, the Company had sales to four customers that individually accounted for more than 10% of its total revenue. These customers had sales of $1.3 million, $1.2 million, $1.1 million and $0.8 million, respectively, which represented 83% of total revenues in the three months ended June 30, 2023. In the six months ended June 30, 2023, the Company had sales to four customers that individually accounted for more than 10% of its total revenue. These customers had sales of $2.2 million, $2.1 million, $1.9 million and $1.9 million, respectively, which represented 87% of total revenues in the six months ended June 30, 2023. </p>
CY2024Q2 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Liability
FairValueDisclosureOffbalanceSheetRisksAmountLiability
0
us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (ASC 606). The provisions of ASC 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described later in this section and in the Accounts Receivable and Allowance policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Twirla is sold to customers at the wholesale acquisition cost (“WAC”). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Distribution services fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prompt pay and other discounts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product returns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chargebacks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rebates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-payment assistance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 606, the Company must make judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relied on quantitative and qualitative data from various internal and external sources to estimate its variable consideration. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The specific considerations that the Company uses in estimating these amounts related to variable considerations are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distribution services fees</span> – The Company pays distribution service fees primarily to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase<span style="white-space:pre-wrap;"> amount. The Company records these fees as contra accounts receivable on the balance sheet. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prompt pay and other discount</span>s – The Company incentivizes its customers to pay their invoices on time through prompt pay discounts. These discounts are an industry standard practice and the Company offers a prompt pay discount to each wholesale distributor customer. The specific prompt pay terms vary by customer and are contractually fixed. Prompt pay discounts are typically taken by the Company’s customers, so an estimate of the discount is recorded at the time of sale based on the WAC. Prompt pay discount estimates are recorded as contra accounts receivable on the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product returns</span> – Customers have the right to return product that is within six months or less of the labeled expiration date or that is past the expiration date by no more than twelve months. Twirla was commercially launched in December 2020, an estimate for product returns as of June 30, 2024 was made based on: (i) data provided to the Company by its distributors (including weekly reporting of distributors’ sales and inventory held by distributors that provided the Company with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies and other providers), (ii) information provided to the Company from retail pharmacies, (iii) data provided to the Company by third-parties including a third-party data provider which collects and publishes prescription data (iv) expired returns credits issued to date, and (v) the estimated remaining shelf life of Twirla previously shipped and currently being shipped to distributors. Estimated product returns are recorded as accrued expenses on the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chargebacks</span> – Certain covered entities and government entities will be able to purchase the product at a price discounted below WAC. The difference between the government or covered entity purchase price and the wholesale </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">distributor purchase price of WAC will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra accounts receivable on the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rebates</span> – The Company is subject to mandatory and negotiated discount obligations under the Medicaid and VA/DOD programs. The rebate amounts for these programs are determined by statutory requirements or contractual arrangements. Rebates are owed after the product has been dispensed to an end user and the Company has been invoiced. Rebates are typically invoiced in arrears. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. Rebate estimates are recorded as accrued expenses on the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Co-payment assistance</span> – The Company offers a co-payment assistance program to commercially insured patients whose insurance requires a co-payment to be made when filling their prescription. This is a voluntary program that is intended to provide financial assistance to patients meeting certain eligibility requirements. The Company estimates the amount of co-payment assistance based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Co-payment assistance estimates are recorded as accrued expenses on the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions for the revenue reserves described above totaled $7.2 million and $6.3 million for the three months ended June 30, 2024 and 2023, respectively, and $15.9 million and $10.8 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, reserves on the balance sheet associated with variable consideration were $7.5 million. <span style="white-space:pre-wrap;"> </span></p>
CY2024Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
7200000
CY2023Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
6300000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
15900000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
10800000
CY2024Q2 agrx Reserve For Variable Consideration
ReserveForVariableConsideration
7500000
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6660
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
24856
CY2022Q2 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
4243
CY2024Q1 agrx Warrants Exercised
WarrantsExercised
100000
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9823057
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9823057
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5195967
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5195967
agrx Fair Value Transfers Between Level1 Level2 And Level3
FairValueTransfersBetweenLevel1Level2AndLevel3
0
agrx Fair Value Transfers Between Level1 Level2 And Level3
FairValueTransfersBetweenLevel1Level2AndLevel3
0
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
134000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
441000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1118000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
402000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1252000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
843000
CY2024Q2 agrx Gross To Net Accruals
GrossToNetAccruals
7507000
CY2023Q4 agrx Gross To Net Accruals
GrossToNetAccruals
6492000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
954000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
832000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
935000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1807000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9396000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9131000
CY2024Q2 agrx Lessee Finance Lease Number Of Finance Leases
LesseeFinanceLeaseNumberOfFinanceLeases
0
CY2024Q2 agrx Lessee Operating Lease Number Of Operating Leases
LesseeOperatingLeaseNumberOfOperatingLeases
1
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2024Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
89000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
89000
us-gaap Operating Lease Expense
OperatingLeaseExpense
178000
us-gaap Operating Lease Expense
OperatingLeaseExpense
178000
us-gaap Operating Lease Payments
OperatingLeasePayments
177000
us-gaap Operating Lease Payments
OperatingLeasePayments
154000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.118
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
199000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
101000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
300000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
289000
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
20000000.0
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
20000000.0
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1650000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
23000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
112000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1515000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1515000
CY2024Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2023Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
372000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
679000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46605134
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
932101
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
284000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
482000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
618000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
979000
CY2024Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
209400000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011904-index-headers.html Edgar Link pending
0001558370-24-011904-index.html Edgar Link pending
0001558370-24-011904.txt Edgar Link pending
0001558370-24-011904-xbrl.zip Edgar Link pending
agrx-20240630.xsd Edgar Link pending
agrx-20240630x10q.htm Edgar Link pending
agrx-20240630xex31d1.htm Edgar Link pending
agrx-20240630xex31d2.htm Edgar Link pending
agrx-20240630xex32d1.htm Edgar Link pending
agrx-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
agrx-20240630_cal.xml Edgar Link unprocessable
agrx-20240630_def.xml Edgar Link unprocessable
agrx-20240630_lab.xml Edgar Link unprocessable
agrx-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
agrx-20240630x10q_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending